Cambridge-based Jounce Therapeutics, Inc. is making waves in the clinical-stage immunotherapy arena, as their cutting edge research targets the development of groundbreaking therapies to combat cancer. Their current focus lies on vopratelimab, a monoclonal antibody that is currently undergoing Phase II clinical trials. This clinical-stage drug is designed to bind to Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which could provide a breakthrough in cancer treatment. But that's not all - the company is also in the process of developing JTX-8064, a monoclonal antibody that targets leukocyte immunoglobulin like receptor B2, a cell surface receptor expressed on macrophages, as well as Pimivalimab, an anti-PD-1 antibody for combination therapy. Looking to the future, Jounce also has a range of promising preclinical products in their pipeline, including JTX-1484, a drug designed to reduce myeloid-mediated immune suppression, and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression while also activating T and NK cells. Founded in 2012, Jounce Therapeutics Inc. is quickly emerging as a major contender in the field of immunotherapy, with their groundbreaking work potentially changing the face of cancer treatment forever.
Jounce Therapeutics's ticker is JNCE
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Jounce Therapeutics
It is jouncetx.com
Jounce Therapeutics is in the Healthcare sector
Jounce Therapeutics is in the Biotechnology industry
The following five companies are Jounce Therapeutics's industry peers: